Loading financials from SEC filings…
Drug manufacturers · Healthcare
Net income was −$12M.
Last 5 fiscal years
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Research & development | 2.5 | 1.6 | 1.1 | 0.9 | 1.3 |
| Operating income | −7.6 | −6.3 | −4.7 | −3.8 | −11.7 |
| Pre-tax income | −7.6 | −6.1 | −4.4 | −3.6 | −11.7 |
| Net income | −7.4 | −5.9 | −4.3 | −3.6 | −11.7 |
| Diluted EPS | −0.58 | −1.19 | −0.87 | −0.72 | −2.37 |
| Diluted shares | 12.8 | 494 | 494 | 494 | 495 |
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 6.4 | 1.6 | 3.0 | 2.4 | 14.2 |
| Current assets | 16.4 | 11.6 | 8.1 | 4.9 | 14.2 |
| Net PP&E | 0.7 | 0.4 | 0.1 | 0.2 | 0.1 |
| Total assets | 18.0 | 12.6 | 8.4 | 5.8 | 14.7 |
| Current liabilities | 0.6 | 0.6 | 0.2 | 0.7 | 1.3 |
| Total liabilities | 0.9 | 0.6 | 0.2 | 0.9 | 1.4 |
| Shareholders' equity | 17.1 | 12.0 | 8.2 | 4.9 | 13.3 |
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Operating cash flow | −5.3 | −5.0 | −4.0 | −3.1 | −7.7 |
| Capital expenditure | 0.8 | 0.0 | 0.0 | 0.2 | – |
| Free cash flow | −6.0 | −5.0 | −4.0 | −3.3 | – |
| Depreciation & amortisation | 0.2 | 0.3 | 0.3 | 0.1 | 0.1 |
| Stock-based compensation | 2.8 | 0.9 | 0.4 | 0.2 | 3.2 |
| Fiscal year | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −43.6% | −48.8% | −52.3% | −73.7% | −87.7% |
| ROCEEBIT ÷ (assets − current liabilities) | −43.7% | −52.2% | −57.5% | −74.0% | −87.4% |
| Cash conversion (CFO ÷ net income) | 0.71x | 0.85x | 0.93x | 0.87x | 0.66x |
| Current ratio | 28.5x | 19.1x | 41.9x | 7.39x | 10.8x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.